Publication
Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo
Publications associées (33)
Effect of the Synaptic Plasma Membrane on the Stability of the Amyloid Precursor Protein Homodimer
Matteo Dal Peraro, Alessandro Barducci, Thomas Lemmin, Martina Audagnotto
The proteolytic cleavage of the transmembrane (TM) domain of the amyloid precursor protein (APP) releases amyloid-beta (A beta) peptides, which accumulation in the brain tissue is an early indicator of Alzheimer's disease. We used multiscale molecular dyna ...
Amer Chemical Soc2016Structural differences of amyloid-beta fibrils revealed by antibodies from phage display
Background: Beside neurofibrillary tangles, amyloid plaques are the major histological hallmarks of Alzheimer's disease (AD) being composed of aggregated fibrils of beta-amyloid (A beta). During the underlying fibrillogenic pathway, starting from a surplus ...
Biomed Central Ltd2015Detection of Alzheimer’s disease amyloid-beta plaque deposition by deep brain impedance profiling
Philippe Renaud, Patrick Fraering, Amélie Barbara Hildegarde Béduer, Sébastien Mosser, Pierre Joris
OBJECTIVE: Alzheimer disease (AD) is the most common form of neurodegenerative disease in elderly people. Toxic brain amyloid-beta (ASS) aggregates and ensuing cell death are believed to play a central role in the pathogenesis of the disease. In this study ...
Iop Publishing Ltd2015A novel encapsulation device for peripheral implantation of antibody-secreting cells
Alzheimer’s disease (AD) is the most prevalent form of dementia in the elderly. As populations are aging in most parts of the world, the number of people with Alzheimer’s disease is expected to dramatically increase. This devastating neurodegenerative diso ...
EPFL2013Transgenic expression of beta 1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice
Maurizio Molinari, Paolo Paganetti
Heterologous expression of the functional amyloid beta (A beta) antibody beta 1 in the central nervous system was engineered to maximize antibody exposure in the brain and assess the effects on A beta production and accumulation in these conditions. A sing ...
Elsevier Science Inc2013Therapeutic antibodies targeting app-c99
Lorène Aeschbach, Patrick Fraering, Tristan Bolmont, Jemila Houacine
The present invention relates to an isolated and/or purified antibody, antibody fragment or derivative thereof able to block the gamma-secretase-dependent processing of the amyloid precursor protein (APP) and to pharmaceutical compositions containing said ...
2012Selective neutralization of APP-C99 with monoclonal antibodies reduces the production of Alzheimer's Aβ peptides
Lorène Aeschbach, Patrick Fraering, Tristan Bolmont, Jemila Houacine
The toxic amyloid-β (Aβ) peptides involved in Alzheimer's disease (AD) are produced after processing of the amyloid precursor protein-C-terminal fragment APP-C99 by γ-secretase. Thus, major therapeutic efforts have been focused on inhibiting the activity o ...
Elsevier Science Inc2012Development of a Small D-Enantiomeric Alzheimer's Amyloid-beta Binding Peptide Ligand for Future In Vivo Imaging Applications
Alzheimer's disease (AD) is a devastating disease affecting predominantly the aging population. One of the characteristic pathological hallmarks of AD are neuritic plaques, consisting of amyloid-beta peptide (A beta). While there has been some advancement ...
Public Library Science2012